X4 Pharmaceuticals (XFOR) Change in Account Payables (2017 - 2026)

X4 Pharmaceuticals (XFOR) has reported Change in Account Payables for 10 consecutive years, with -$1.1 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Change in Account Payables rose 66.89% year-over-year to -$1.1 million; the trailing twelve-month figure through Jun 2026 stood at -$3.8 million (down 1122.01% YoY), and the FY2025 full-year result was -$3.0 million, down 941.61% from the prior year.
• Change in Account Payables declined to -$1.1 million in Q2 2026 per XFOR's latest filing, from -$624000.0 in the prior quarter.
• Across five years, Change in Account Payables topped out at $3.9 million in Q4 2022 and bottomed at -$3.4 million in Q2 2025.
• Historically, Change in Account Payables has averaged -$20555.6 across 5 years, with a median of $41000.0 in 2024.
• The sharpest annual moves came in 2022 and 2025: Change in Account Payables sank 3000.0% in 2022, then jumped 61800.0% in 2025.
• Over 5 years, Change in Account Payables stood at $3.9 million in 2022, then plunged by 79.31% to $808000.0 in 2023, then slumped by 90.35% to $78000.0 in 2024, then surged by 723.08% to $642000.0 in 2025, then plunged by 277.57% to -$1.1 million in 2026.
• According to Business Quant data, Change in Account Payables over the past three periods registered -$1.1 million, -$624000.0, and $642000.0 for Q2 2026, Q1 2026, and Q4 2025 respectively.